


GMC registered physician with 15 years of experience as Medical Doctor, including 5 years of clinical drug development in Pharma and CRO as Investigator, Senior Research Physician and Independent Consultant, in addition to 10 years of experience as General and Vascular Surgeon.
Broad experience in different stages of drug development in diversity of therapeutic areas including, but not limited to, Respiratory, Cardiovascular, Diabetes, Urology, Oncology, Vaccines and Neurosciences.
A detailed CV can be provided upon request
Qualifications:
MSc in Clinical Research Administration (2011) - Universtiy of Liverpool, UK
Thesis: “Hypertension Trials - Safety Reporting”
Diploma in Pharmaceutical Medicine (2011) - Royal College of Physicians of London, UK
Postgraduate Course in Pharmaceutical Medicine - Cardiff Univeristy - 2009-10.
Certificate of Completion of Basic Surgical Training - Royal College of Surgeons, UK.
MRCS (2006) - Diploma in General Surgery, Royal College of Surgeons, UK
MBBS/MD (1999) - University of Mumbai, India
Experience:
Global Medical Specialist, Respiratory Portfolio, Novartis
Senior Research Physician MEDINOVA, London a specialised CRO
Senior Research Physician MAC UK Neurosciences, a specialised CRO
Clinical Research Physician Synexus, a global CRO
Research Physician, Gateshead University Hospital
10 years of clinical practice experience at Academic and District Hospitals as General and Vascular Surgeon
Publications
Bagul NB, Kirkham JJ. The reporting of harms in randomized controlled trials of hypertension using the CONSORT criteria for harm reporting. Clinical and Experimental Hypertension. 2012; 34(8):548-54
Binkley N et.al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012 Aug; 27(8):1821-9.
Ralston et.al. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency. Calcified Tissue Int. 2011 Jun; 88(6):485-94.